Abstract Library

#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors

Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Emelianova G, Dronova E,

Keywords: neuroendocrine tumor, pancreas, sunitinib, somatostatin analogues,

#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia

Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Gorbunova V, Orel N, Emelianova G,

Keywords: neuroendocrine tumors, everolimus, uni- and multivariate analysis,

#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors

Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Kuznetsova A, Gorbunova V, Orel N, Emelianova G, Markovich A,

Keywords: lung neuroendocrine tumors, Everolimus,